Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
William M. Hart, MD, Patricia Doerr, MD, Yuxiao Qian, MD, and Peggy M. McNaull, MD
When errors happen, too often clinicians are at odds with each other about how to respond to a patient or a patient’s loved ones after that patient suffers harm.
AMA J Ethics. 2020;22(4):E298-304. doi:
10.1001/amajethics.2020.298.
Tabitha E. H. Moses, MS joins Ethics Talk to discuss her article, coauthored with Dr Arash Javanbakht: “How Should Clinicians Determine a Traumatized Patient’s Readiness to Return to Work?”